Brief: Cumberland Pharma- Released Series Of Case Reports Describing Effectiveness Of Vibativ In Treating Secondary Bacterial Infections In Covid-19 Patients
21/06/2021 14:21
June 21 (Reuters) - Cumberland Pharmaceuticals Inc CPIX.O :
* CUMBERLAND PHARMA- RELEASED SERIES OF CASE REPORTS
DESCRIBING
EFFECTIVENESS OF VIBATIV IN TREATING SECONDARY BACTERIAL
INFECTIONS IN COVID-19 PATIENTS
Source text for Eikon: ID:nPn1YdgSYa
Further company coverage: CPIX.O
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Cumberland Pharmaceuticals
See all newsBrief: Cumberland Pharmaceuticals Announces Assist-Ssc Trial Top-Line Results
Cumberland Pharmaceuticals Q2 loss widens after Apotex transaction
Brief: Cumberland Pharmaceuticals Announces Special Dividend Of $1.50 Per Share
Cumberland Pharmaceuticals Q1 revenue up 5%; to sell FDA‑approved brands to Apotex for $100 mln
NASDAQ RESUMED AT 09:38 AM